EntreChem closed a financing round thanks to a mix of private and public funding, in a deal that significantly strengthens the capacities of research and development of the biotech company. New shareholders include family offices and owners of industrial, long-running businesses, like NalonChem SA, as well as Alvargonzález SA and... read more →
Sep
16
Feb
04
AENOR (Spanish Association for Standarization and Certification) has granted EntreChem with the UNE-166002 certification, an standard for the implementation of a quality R+D+I system that contributes to optimising an organisation's technological research, development and innovation processes, enabling emerging technologies or new technologies applied to the sector to be recognised and... read more →
Jan
25
The Centre for the Development of Industrial Technology (CDTI) has awarded EntreChem with a NEOTEC-2 grant, consisting on a special loan (a reimbursable loan) of 658.050 EUR for development of new antitumoral molecules. This loan carries a 0% interest rate and its reimbursable anytime contingent to positive cash-flow of the... read more →
Jul
13
EntreChem data on the first family of antitumoral molecules being developed by the company have been selected for a poster presentation at the 20th ENA symposium held in Geneva from 21-24 October 2008. The principal investigator is Dr. Carlo Catapano, from the Istituto Oncologico della Svizzera Italiana (IOSI) in Bellinzona... read more →
Jul
31
EntreChem has entered a development agreement with Instituto Biomar SA (León, Spain) to exploit EntreChem proprietary technology regarding the use of combinatorial biosynthesis and biotransformations for the generation of molecular diversity on certain Instituto Biomar proprietary compounds. About Instituto Biomar SA: Instituto Biomar... read more →
Oct
25
EntreChem has entered a collaborative agreement with Laboratoires Servier (Paris, France) to exploit EntreChem proprietary technology regarding the use of combinatorial biosynthesis and biotransformations for the generation of molecular diversity on Laboratoires Servier proprietary compounds. About Servier: Les Laboratoires Servier is the leading... read more →
Sep
19
Dr. Francisco Morís, co-founder and CEO of EntreChem, is interviewed in the September issue of Nature Biotechnology. The issue runs a Special Report about Biotech companies in Spain. Read the full article and Dr. Morís comments Nature Biotechnology, September 2006 issue nature_spain_report.pdf (3.1 MB)
Sep
04
Professor of biology José Salas and coworkers at the University of Oviedo, Spain, use a different tack. They insert into microorganisms plasmids that endow them with the ability to synthesize novel sugars, which are then transferred to natural products by glycosyltransferases. "Because glycosyltransferases are relatively flexible in their ability to... read more →
Jun
22
EntreChem has signed an agreement with The Centre for the Development of Industrial Technology (CDTI) consisting on a reimbursable loan of 400,000 EUR within the NEOTEC program for promotion of newly created companies focused on technology development. The entities that may receive financing in the form of loans granted by... read more →
Apr
01
EntreChem has signed an agreement with the “Sociedad Regional de Promoción” of the Principality of Asturias for a special loan (a “participative loan”) to finance start-up activities of EntreChem. This “participative loan” has an interest rate determined by company profits and its callability is subordinated to the other common creditors.... read more →
